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The human b12 IgG1, specific for the CD4 binding site of the gp120 of HIV-1, was prepared by recombinant DNA
technology. It had a high neutralization rate constant (03.5 1 105 M01 sec01), although this is about 10-fold less than the
values for the best poliovirus or influenza A virus MAbs. The recombinant b12 Fab neutralized well, with about one-tenth
of the activity of b12 IgG. The mechanisms by which b12 IgG1 and its Fab neutralize HIV-1 IIIB on C8166 cells have been
investigated. Neither inhibited attachment of virus to the target cell as judged by FACS, immunofluorescence, and ELISA
data. This was controlled using MAb F105, another human IgG1, that did neutralize by inhibiting attachment under our
conditions. The interactions of b12 IgG- and Fab-neutralized virions with target cells were compared with those of nonneutral-
ized virus using a number of different techniques (fluorescence dequenching of R18-labeled virions, immunofluorescence
of virion gp41 and p24 antigens, and acquisition of resistance to removal of virions from the cell by protease). These and
the inhibition of HIV-1-mediated cell–cell fusion all demonstrated that b12 IgG neutralized by inhibiting the primary fusion-
uncoating mechanism. However, the interactions of b12 Fab-neutralized and nonneutralized virions with C8166 cells were
indistinguishable. Thus b12 Fab did not inhibit fusion uncoating, and by inference inhibited a stage of infection that occurs
after the entry of the virion core into the cytoplasm. It is therefore possible that b12 IgG kills HIV-1 twice over, by fusion-
inhibition and by inhibiting the postentry event proposed for the Fab. The mechanism of neutralization of b12 Fab and of
other MAbs that neutralize in a similar way and why b12 Fab and IgG neutralize by different mechanisms are discussed.
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INTRODUCTION per virion) can also determine the mechanism of neutral-
ization. Other factors, such as multivalent binding of anti-
Neutralization is an in vitro phenomenon, in which neu- body to virion, depend both on properties of the virion
tralizing antibody binds to the surface of a virus particle (epitopes spaced neither too close together nor too far
and causes loss of infectivity (Dimmock, 1993, 1995). The apart) and of the neutralizing antibody (molecular interac-
epitope involved is usually protein but can be carbohy- tions of epitope and paratope such that one arm of a
drate. Nonneutralizing antibodies also exist, which im- bivalent antibody is oriented away from the virion). The
plies that neutralization results from the binding of anti- situation is made more complex because any of the pa-
body to a specific site on the virion. Neutralization can rameters mentioned may operate in combination. Finally
also be indirect and can result, for example when anti- the host and the target cell can determine qualitatively
bodies bind complement components. Thus nonneu- or quantitatively the extent of neutralization (Dimmock,
tralizing antibodies can become neutralizing, and neu- 1993, 1995; Sawyer et al., 1994).
tralizing antibodies can neutralize both indirectly and di- The commonly regarded mechanism of neutralization
rectly. by steric inhibition of the interaction between virus and
There are many mechanisms by which antibodies can its cell receptor occurs only rarely, and a direct quantita-
directly neutralize virus infectivity, and any one virus can tive relationship has been established for only a few
be neutralized in a variety of different ways depending virus-IgG monoclonal antibody (MAb) combinations (e.g.,
on a number of variables. Viruses have several antigenic Newcastle disease virus with some but not all of its
(neutralization) sites, each consisting of a number of epi- MAbs, Iorio et al., 1989; rhinovirus type 14 with MAb 17-
topes, and these may be present on one or more surface 1A, Smith et al., 1993; Table 1 of Dimmock, 1993). At high
proteins. It is likely that the mechanism of neutralization concentration the larger polymeric antibodies, IgA and
will be influenced by the functional role of the domain IgM, inhibit attachment by binding to the virion by one
recognized by antibody. In addition, properties of the anti- of their immunoglobulin units and projecting radially from
body (e.g., paratope, isotype, number of molecules bound the surface of the virion. At lower concentrations they
bind multivalently and are no more able to inhibit attach-
ment than IgG (Dimmock, 1993). Usually neutralizing anti-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: /44 1 203 523568. E-mail: nd@dna.bio.warwick.ac.uk. bodies inhibit a stage of infection which occurs postat-
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tachment, such as primary uncoating by fusion or other including isolates which were resistant to neutralization
by pooled human sera from HIV-infected patients (Burtonmeans, and postprimary uncoating events.
Many neutralizing MAbs to HIV-1 have been described. et al., 1994). Here we find that b12 IgG did not inhibit
attachment of neutralized virus to the target cell, but in-The major neutralization sites on gp120 are located on
the V3 loop and in the region of the CD4-binding site, hibited the fusion entry process in direct proportion to
the extent of neutralization. Neutralizing amounts of b12with minor sites on the V1/V2 loops. There is also at
least one important site on the transmembrane gp41 (re- Fab inhibited neither attachment to, nor fusion entry of
virus into the target cell and, by inference, inhibited aviewed by Moore and Ho, 1995; Sattentau and Moore,
1995). There have been few studies of how anti-HIV-1 postentry stage of infection.
antibodies neutralize (see reviews by Poignard et al.,
1996; Sattentau, 1996). Most of the ‘‘CD4 binding site MATERIALS AND METHODS
MAbs’’ are defined by their ability to block attachment of
Cellssoluble recombinant (sr) gp120 to srCD4 but only a few
have been tested for their ability to block attachment of The CD4/ human T cell lines, C8166 and H9 (MRC
infectious virus to susceptible target cells. While some AIDS Reagent Project (ARP)), and the CD40 T cell line,
human postinfection sera have been shown to block at- A2.01 (a kind gift of Dr Q Sattentau), were grown in RPMI
tachment of HIV-1 to cells (McDougal et al., 1986; Ho et 1640 (Gibco-BRL Life Technologies, Paisley, UK) sup-
al., 1988; Skinner et al., 1988; Montefiori et al., 1993), few plemented with 10% heat inactivated fetal calf serum
other antibodies appear to have this property. MAb F105 (HIFCS), glutamine (2 mM), penicillin (100 U/ml), and
(Posner et al., 1991), and some other binding site antibod- streptomycin (100 mg/ml). Stably transfected HeLa cells
ies blocked attachment of virus to lymphoblastoid cells expressing the T4(CD4) protein (HeLa-T4(CD4), Maddon
(H9 and C8166), but only F105 inhibited attachment in et al., 1986) were obtained from Dr. R Axel via the MRC-
proportion to its neutralizing activity. V3-specific MAbs ARP and grown in DMEM with 5% HIFCS, 4 mM gluta-
do not inhibit the association of srgp120 and srCD4, and mine, and 1 mg/ml Geneticin (Gibco-BRL).
the few which have been examined do not inhibit attach-
ment of virus to cells (0.5b, 9284, Skinner et al., 1988; Virus
BAT123, Sun et al., 1989; F58, ICR41.1i, Armstrong et al.,
HIV-1 IIIB was propagated by cocultivating chronically1996). The HIV-1 genome enters cells by neutral pH fu-
infected and uninfected H9 cells at a ratio of 1:4 for 72sion of the viral and plasma membranes (Marsh and
hr at 357. Cells were placed in fresh medium 24 hr priorPelchen-Matthews, 1993). Many V3-specific antibodies
to harvesting to minimize the presence of free viral pro-inhibit HIV-1-mediated cell fusion, but only one study has
teins, and tissue culture fluids (TCFs) were centrifugedshown that neutralization correlated quantitatively and
to remove cells and debris. Infectivity was measured indirectly with the inhibition of virus fusion entry into the
C8166 cells immobilized to 96-well plates with poly-L-cell (Armstrong et al., 1996). In the same study, another
lysine after 3 days incubation at 357 by counting syncytianeutralizing V3-specific MAb, ICR41.1i, did not inhibit fu-
(McLain and Dimmock, 1994), or using nonanchoredsion. Knowledge of how antibodies inactivate infectivity
cells and incubating for 4 days at 357, and scoring foris desirable in order to understand how they might be
the presence of syncytia in an end-point assay. Non-best employed in passive administration to prevent and/
virion-associated p24 was removed by gel filtration ofor combat HIV-1 infection in vivo, and to determine the
virus through Sephacryl S-1000 Superfine (Pharmacia Bi-nature of antibodies that future vaccines should aim to
otech AB, Uppsala, Sweden). Fractions (approximatelystimulate. Antibodies can also be regarded as inhibitors
115 ml) were analyzed by ELISA for p24 (see below) andwhich allow investigation of the early processes of infec-
for infectious virus. Figure 1 shows a typical elution pro-tion, and knowledge of how they act may lead to the
file. The majority (92%) of p24 protein coeluted with infec-development of antivirals that mimic their mode of action.
tious virus; this may be an underestimate since the ODHere we report an investigation of the mechanism by
was near background for many fractions. These very lowwhich a human recombinant IgG1 and Fab (Burton et al.,
levels of free p24 protein agree with previous reports1991, 1994) neutralize HIV-1 strain IIIB. On the basis of
(Moore et al., 1990; McKeating et al., 1991).competition and mutagenesis studies the epitope of this
MAb has been localized to a region of the CD4 binding Antibodies
site (Barbas III et al., 1992, 1993; Roben et al., 1994).
The Fab exhibited high neutralizing activity and cross- B12 Fab is a recombinant antibody produced by the
phage display method from a combinatorial library pre-neutralized several strains of HIV-1, including a number
of primary isolates (Barbas III et al., 1994; Roben et al., pared from the bone marrow of a long-term asymptom-
atic HIV-1 seropositive donor and identified by recogni-1994). Conversion of the Fab to IgG1 conferred upon it
the ability to neutralize a much wider range of primary tion of srgp120 of HIV-1 IIIB. Fab was expressed in Esch-
erichia coli (Burton et al., 1991). The heavy chain genevirus isolates at reasonably low antibody concentration,
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FACS analysis to show the effect of neutralizing
antibody on the attachment of virus to cells and
demonstration that neutralized virus was
attaching to CD4 receptors
Fcg receptors were blocked with normal rat IgG as
described above. Cells were washed and incubated with
an anti-CD4 MAb Q4120 (40 mg/106 cells/ml; MRC-ARP;
Healy et al., 1990) for 2 hr at 47 and then used without
washing in attachment assays. Purified nonneutralized
virus (2 1 104 sfu) or virus neutralized with b12 IgG were
added to 106 cells and attachment was allowed to pro-
ceed for 2 hr at 47. MAb F105 (human IgG1) which blocks
attachment of neutralized HIV-1 to cells was used as a
FIG. 1. Analysis of the p24 content of tissue culture supernatant from control (Posner et al., 1991). Cells were washed thor-
HIV-1-infected H9 cells by gel filtration on Sephacryl S-1000 Superfine. oughly with PBS and fixed and permeabilized in methanol
Sequential 3 drop fractions were analyzed for p24 content by ELISA overnight at0207. Fixed cells were incubated with sheep
(l) and for infectious virus (j). The arrow marks the position of free
antiserum to HIV-1 p24 (1 mg/ml; D7320, Aalto Biorea-p24 protein.
gents, Dublin, Eire) for 1 hr at room temperature. Cells
were washed and incubated for 1 hr with biotinylated
donkey anti-sheep antibody (1/200; Amersham Interna-of b12 Fab was converted to the complete human heavy
tional plc, Amersham, UK) and then streptavidin-fluores-chain G1 gene by splicing to the relevant DNA, and the
cein (1/200; Amersham International plc, Amersham, UK).complete IgG1 protein was expressed in Chinese ham-
Bound virus was detected using a Becton–Dickinsonster ovary cells (Burton et al., 1994). Recombinant anti-
FACStar, exciting at about 488 nm and measuring emit-bodies were stored at 0707. All experiments (with the
ted light of 515–545 nm via the fluorescence 1 channel.exception of the data in Fig. 8) used the same stock
Both the anti-p24 antibody and the biotinylated anti-of recombinant antibodies. However, some neutralizing
sheep antibody were absorbed with methanol-fixed H9activity was lost on storage so the specific neutralizing
cells (which lack Fc receptors) prior to use.activity is seen to vary through the paper. Human IgG
from HIV-1 seronegative donors was prepared by affinity
Immunofluorescence study of the attachment andchromatography using protein G–Sepharose (Gam-
entry of nonneutralized virus into HeLa-T4(CD4) cells,mabind Plus, Pharmacia Biotech AB, Uppsala, Sweden).
and the effect of neutralizing b12 IgG and FabProtein concentrations were determined spectrophoto-
metrically or using a dye binding procedure (Bio-Rad Immunofluorescence was carried out as described by
Laboratories, Mu¨nchen, Germany). Armstrong et al. (1996). Briefly we used HeLa-T4(CD4)
cells since lymphoblastoid cells, such as C8166 cells,
Kinetic neutralization assays have very little cytoplasm and are unsuitable for following
the intracellular location of viral components after infec-
Virus (1.2 1 103 syncytium forming units per ml (sfu/ tion. Virus was concentrated using Centriprep 100 con-
ml)), was mixed with a dilution of antibody and incubated centrators (Amicon, Stonehouse, UK) and stored over liq-
at 357. At intervals an aliquot was removed and assayed uid nitrogen. Before use virus was passed through Seph-
by counting syncytia on monolayers of C8166 cells acryl S-1000 Superfine to remove free viral proteins. Then
(McLain and Dimmock, 1994). There was no loss of infec- 2.5 1 104 sfu were added to 2 1 105 cells on 16-mm-
tivity of a virus control incubated without antibody. diameter coverslips which had been grown overnight in
Assays were the mean of six replicates. the absence of Geneticin. Based on our estimate of 3000
physical particles: 1 infectious unit (T. L. McInerney, un-
published data), the inoculum approximated to 300 physi-Blocking of Fcg receptors on C8166 cells
cal particles per cell. Twenty-five microliters of virus was
incubated for 1 hr at 357 with an equal volume of IgG orTo prevent the possibility of virus–IgG complexes at-
taching to Fcg receptors present on C8166 cells, we Fab that gave approximately 99% neutralization. This was
then incubated with cells for 2 hr at room temperature.used 1 mg/ml of normal rat IgG (100 ml/106 cells) for 1
hr at 47 to saturate FcgRI receptors, and then with 10 Samples were washed to remove virus and either fixed
immediately or incubated at 357 for 3 or 6 hr to permitmg/ml heat-complexed (657, 30 min) normal rat IgG to
saturate FcgRII and RIII receptors (McLain and Dim- virus internalization before fixing. Fixation consisted of
0.4% paraformaldehyde for 1 hr at 47 and 0.4% paraform-mock, 1997). Cells were then washed once in cold me-
dium and used in various assays described below. aldehyde overnight. Cells were then treated with 0.2%
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Empigen for 0.5 hr washed and stored at 0207. Nonspe- 0). Fusion was measured by scoring syncytia (see below)
under low power magnification. Fusion was allowed tocific binding of antibody etc. was prevented by blocking
with 1% glycine and 5% sheep serum. Virion p24 was proceed in samples for a further 3 hr at 357, then samples
were fixed with 2% formaldehyde. Cells were viewed un-detected using biotinylated sheep anti-p24 antibody
(MRC-ARP), followed by streptavidin-fluorescein (Amer- der low power microscopy, and those with a diameter at
least twice that of a normal cell were considered to besham Life Sciences), and gp41 with the human MAb
2F5 (Muster et al., 1993) and a monoclonal biotinylated the product of cell–cell fusion. Staining and counting
showed that these contained 3 to 8 nuclei (mean  4.7mouse anti-human IgG Fc (Sigma) followed by streptavi-
din-fluorescein. The latter did not detect cells with nuclei; data not shown). The number of fused cells oc-
curring spontaneously in the nonincubated control wasattached b12 Fab-neutralized virus, and very weakly with
cells with attached b12 IgG-neutralized virus. Addition of subtracted. Over 1000 cells were counted for each sam-
ple. In three experiments, there was an average 0.9%anti-gp41 to the latter increased fluorescence many fold.
Although the fluorescence was apparent to the eye, it syncytia in the unincubated controls and 5.7% in the incu-
bated fused controls (data not shown). A total of approxi-was too weak to photograph, so the signal was amplified
with a mouse anti-fluorescein MAb (Sigma), biotinylated mately 103 cells was counted from each sample and
percentage fusion calculated as the number of syncytia/sheep anti-mouse IgG, and streptavidin-fluorescein.
Cells were examined and photographed under UV light total number of cells counted. The baseline number of
syncytia was subtracted from both values. The effect ofusing a Zeiss Axioskop microscope. About 1000 cells
per group were counted to quantitate the distribution of neutralizing b12 antibody on fusion was determined by
adding serial dilutions to infected cells (2 1 104 infectedfluorescence.
cells/100 ml antibody dilution) for 1 hr at 357 and then
Fusion of HIV-1 virions with cells as measured by proceeding as described above. Neutralization assays
R18 fluorescence dequenching and the effect of were carried out in parallel using the same antibody
neutralizing antibody dilutions as for the fusion experiments. Antibody dilutions
and virus (700 sfu) were incubated together for 1 hr and
Virus was purified by ultracentrifugation and incubated
then incubated for a further 3 hr at 357 with 1.4 1 105
in 500 ml of 630 mM octadecyl rhodamine B chloride (R18:
C8166 cells. Free antibody and unattached virus were
Molecular Probes Europe BV, Leiden, The Netherlands)
removed by centrifugation, cells dispensed, and neutral-
prepared by diluting an ethanolic solution of R18 1/100
ization determined after 3 days incubation at 357.
in PBS for 1 hr at room temperature in darkness to allow
R18 to dissolve in the lipid bilayer of the virion. Free R18 Detection of viral capsid protein p24 in cell lysates
was removed by pelleting virus over 20% sucrose. R18-
Sheep antiserum to HIV-1 p24 (D7320; Aalto Biorea-
labeled virus lost no infectivity during these procedures.
gents, Dublin, Eire) was bound to wells of ELISA plates
In agreement with others (Hoekstra et al., 1984; Loyter
(Immulon 2; Dynatech Laboratories, Billingshurst, UK) by
et al., 1988) we found that solubilization of virus in Triton
incubating 1 mg/well in 100 mM NaHCO3 , pH 8.5, at roomX-100 led to 100-fold increase in fluorescence, sug-
temperature overnight. After washing with Tris-buffered
gesting that the R18 was highly self-quenched and incor-
saline (TBS; 0.14 M NaCl, 0.02 M Tris buffer, pH 7.6),
porated in the virus lipid bilayer. R18-labeled HIV-1 or
nonspecific binding sites were blocked with 2% milk pro-
neutralized (1 hr at 357) R18 labeled HIV-1 (1 1 105 sfu)
tein (Marvel; Premier Beverages). In order to assay cell-
was mixed with 5 1 106 C8166 or A2.01 cells (a CD4-
associated virion p24 protein, cell pellets were lysed by
negative T cell line) and incubated at 357. At intervals,
suspending in 600 ml of 1% Empigen detergent in PBS
aliquots of 1 1 106 cells were removed, washed with
at 567 for 30 min. Cell lysates (100 ml) were added to
PBS, and a sample was taken to determine the amount
wells and plates held at room temperature overnight.
of neutralization. The remainder were fixed with 2% para-
Recombinant p24 (MRC ARP) was included as a standard
formaldehyde. Fluorescence was determined using a
when required. Wells were washed with TBS containing
Becton–Dickinson FACStar, exciting at about 488 nm
0.05% Tween (TBST) and a biotinylated mouse anti-p24
and measuring emitted light of 560–590 nm via the fluo-
MAb added (100 ml/well; 1/1000 in TBST; MRC-ARP).
rescence 2 channel. Virus was used within a few days
Plates were held for another 2 hr, then wells were
of labeling.
washed and streptavidin-alkaline phosphatase was
added (Amersham, UK). One hour later, this was re-HIV-1-induced cell fusion and the effect of
moved, wells were washed, and substrate was addedneutralizing antibody
[p-nitrophenyl phosphate, 1 mg/ml (Sigma, UK) in 9.7%
diethanolamine, 0.5 M magnesium chloride, pH 9.8C8166 cells were infected with HIV-1 (0.01 sfu/cell)
and incubated for 3 days at 357. These cells (2 1 104) (Pierce, Rockford, IL)]. Plates were incubated at 357 in
the dark and then the optical density was measured atwere then added to noninfected C8166 cells (21 105) and
the baseline level of cell–cell fusion determined (time  405 nm.
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Attachment of virus to C8166 target cells and the
effect of neutralizing antibody
HIV-1 (2 1 104 sfu) was added to 106 C8166 target
cells and incubated for 2 hr at 357 to allow virus to attach
to cell receptors. Unattached virus was removed by cen-
trifugation and cell pellets were washed several times
with phosphate-buffered saline (PBS). Cells were lysed
with 1% Empigen detergent (Calbiochem, Nottingham,
UK) and attachment of virions determined by p24 ELISA.
In order to determine the effect of b12 Fab or IgG on the
attachment of virus to cells, dilutions of antibody (400 ml)
were preincubated with virus (2 1 104 sfu/400 ml) for 1
hr at 357 prior to the addition of cells. All subsequent
steps were as described above. The amount of neutral- FIG. 2. Neutralization of HIV-1 by the b12 IgG (j) and b12 Fab
(h) as determined by the syncytium reduction assay. Neutralization isization in each sample was determined by removing an
expressed as the percentage of the number of syncytia present afteraliquot of virus-inoculated cells and culturing these for 3
incubation for 1 hr with antibody/number of syncytia present in thedays (2 1 104 cells/well) at 357 before counting syncytia. control (antibody free) inoculum. Each point represents the mean of
six replicates.
Removal of HIV-1 attached to C8166 cells by trypsin
We used the method of Krust et al. (1993), except that
that bivalency and hence cross-linking of virus particlesHIV-1 (4 1 104 sfu) or neutralized HIV-1 was added to
or individual gp120 monomers is not required for neutral-C8166 cells (21 106) for 2 hr at room temperature. These
ization with this particular antibody.conditions allowed attachment of virus to cells with mini-
(ii) Kinetics of neutralization. Kinetic neutralizationmal fusion (Armstrong et al., 1996). Nonattached virus
assays were carried out to determine the order of reac-and antibody were then removed by centrifugation. Cells
tion and the neutralization rate constant of b12 IgG andwere then resuspended in 1 ml fresh medium and incu-
Fab (Fig. 3). Note that about 10-fold more Fab than IgGbated for a further 3 hr at 357 to allow fusion of virus and
was used in Fig. 3. The neutralization rate constant 0k,cell membranes. Cells were washed once in medium
was calculated using the expression:without serum and divided into two aliquots: one was
treated with 200 ml of trypsin (1.3 mg/ml; Difco Labora- log10Vt/V0  (0k/2.3D).t
tories, Detroit, MI) at room temperature for 10 min to
where V0 and Vt are the infectivity at times 0 and t,remove any virus attached to the outside of the cells,
respectively, and D is the molar concentration of anti-and the other was incubated with RPMI to measure the
body (Mandel, 1985). Neutralization rate constants fortotal amount of cell-associated virus. One milliliter of
the data in Fig. 3 were 3.3 1 105 M01 sec01 for IgG,RPMI containing 10% FCS was then added to terminate
and 4.3 1 104 M01 sec01 for Fab. Results from threetrypsin activity. Cells were washed, lysed with detergent,
separate experiments yielded average 0k values ofand the amount of p24 protein was determined by ELISA.
3.5 { 0.5 1 105 for IgG and 3.7 { 0.5 1 104 for b12Trypsin routinely removed 90% virus attached to the
Fab. B12 IgG and Fab both neutralized without a signifi-surface of the cell. Data were corrected for the small
cant lag period showing that loss of infectivity pro-fraction of virus which was not removed by treatment
ceeded by pseudo-first order kinetics.with trypsin. IgG from seronegative human donors was
included as a negative control for neutralization. The ex-
B12 IgG does not inhibit the attachment oftent of neutralization was determined by removing an
neutralized virus to C8166 cells, and IgG-neutralizedaliquot of virus-inoculated cells following the first wash
virus attaches via CD4 receptorsand culturing these for 3 days (2 1 104 cells/well) at 357
before counting syncytia. One mechanism by which antibody mediates neutral-
ization of viral infectivity is by blocking attachment of the
RESULTS virus particle to its specific cell receptor. As the epitope
of b12 has been mapped to the CD4 binding site on
Properties of b12 IgG and Fab
srgp120 (Barbas III et al., 1992, 1993; Roben et al., 1994)
such a mechanism would not be unexpected. As a con-(i) Neutralization of HIV-1. B12 IgG and Fab both neu-
tralized HIV-1 well (Fig. 2). On a molar basis the IgG was trol, we determined the effect on virus attachment of MAb
F105, another human IgG1 CD4-binding site-specificapproximately 10-fold more efficient than Fab, with 50%
neutralization at 0.3 and 2.5 nM (or 0.05 and 0.13 mg/ml), MAb like b12, that neutralizes by inhibiting attachment
to the target cell (Posner et al., 1991). However, beforerespectively. The ability of Fab to neutralize indicates
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b12 concentration threefold gave 96% neutralization and
over 70% virions attached to cells. In addition the attach-
ment of HIV-1 neutralized by Fab b12 to 98% to C8166
cells was not inhibited. Saturation of FcgRs with mono-
meric and complexed IgG had no effect on the attach-
ment of b12 IgG- or Fab-neutralized virus (data not
shown).
From the data above we conclude that b12 IgG and
Fab do not neutralize by inhibiting attachment to the tar-
get cell, and that HIV-1 neutralized by these antibodies
attaches to the same domain of the CD4 receptor as
FIG. 3. Kinetics of neutralization of HIV-1 with b12 IgG (j) and b12
Fab (h) on C8166 cells. Virus (1.2 1 103 SFU/ml) was incubated with
1.3 nM IgG or 10 nM Fab at 357 for the indicated times. Infectivity
was determined by counting syncytia after incubation. Vt/V0 is the ratio
between infectivity at time t and that observed in the absence of anti-
body (time 0). There was no loss of infectivity when virus was incubated
alone under the same conditions. Neutralization rate constants (0k)
for the data shown were IgG: 3.3 1 105 M01 sec01 and Fab: 4.3 1 104
M01 sec01. Both linear regression values were ¢0.98.
starting it was necessary to block FcgRI (CD64), FcgRII
(CD32), and FcgRIII (CD16) receptors that are present
on C8166 cells with normal monomeric and complexed
rat IgG to ensure that virus did not attach to cells via its
bound IgG (McLain and Dimmock, 1997). This treatment
does not affect the attachment of nonneutralized virus
(data not shown). MAb F105 in our cells and under our
conditions of neutralization inhibited attachment of neu-
tralized virus to C8166 cells in proportion to the loss of
infectivity. An example of these data using an anti-p24
antibody to locate virions is shown in Figs. 4A and 4B.
FACS analysis showed that b12 IgG-neutralized virus
attached to C8166 cells as efficiently as nonneutralized FIG. 4. FACS analysis of the ability of neutralized HIV-1 to attach to
C8166 cells. (A, B) Virus neutralized by the human IgG1 MAb, F105.virus (Figs. 4C–4E, shaded area). Before examining the
Cellular FcgRs were first blocked by incubating cells with monomericspecificity of attachment of b12 IgG-neutralized virus, we
and complexed rat IgG. (A) compares cells to which nonneutralizedconfirmed that nonneutralized HIV-1 attached poorly
virus has attached at 47 for 2 hr (2 1 104 SFU: shaded area) with
(30%) to cells that lack CD4 (HeLa), compared with HeLa noninoculated cells (broken line). (B) shows that cells inoculated with
cells that express the transfected CD4 gene (data not virus neutralized 88% by 10 mg/ml MAb F105 did not differ from noninoc-
ulated cells in A. The presence of cell-associated virus was determinedshown). To provide a more critical assessment, we then
by FACS analysis. Neutralization was determined by culturing a sampleblocked CD4 receptors on C8166 cells with an anti-CD4
of cells removed from mixtures before fixation and counting syncytiaMAb (Q4120) and compared the extent of attachment of
after 3 days incubation at 357. (C, D, E) Virus neutralized by the human
nonneutralized virus and neutralized virus. Figure 4 IgG1 MAb, b12. Cellular Fcg receptors were first blocked as described
shows that MAb Q4120 completely inhibited attachment above and virus (2 1 104 SFU) incubated with b12 IgG as described
below. Virus–antibody mixtures were inoculated onto C8166 cells orof nonneutralized virus (Fig. 4C, solid line), and of virus
cells treated with the Q4120 anti-CD4 MAb in order to demonstrateneutralized by b12 IgG (Figs. 4D and 4E, solid line), giving
specificity of attachment. Attachment was then allowed to proceed fora very similar trace to that of the noninoculated cell con-
2 hr at 47. The presence of cell-associated virus and neutralization were
trol (Fig. 4C, broken line). Thus b12 IgG does not inhibit determined as above. (C) cell control (broken line); cells inoculated with
attachment to CD4/ cells, despite the fact that its epitope nonneutralized virus (shaded area); cells pretreated with anti-CD4 MAb
and inoculated with nonneutralized virus (solid line). (D) Cells inocu-overlaps the CD4 binding site.
lated with neutralized virus (0.316 mg/ml, shaded area); cells pretreatedThe above data with b12 antibody were confirmed
with anti-CD4 MAb and inoculated with IgG neutralized-virus (solidquantitatively by assaying the amount of virion p24 pro-
line). (E) Cells inoculated with neutralized virus (3.16 mg/ml, shaded
tein attached to C8166 cells by ELISA. Figure 5 shows area); cells pretreated with anti-CD4 MAb and inoculated with IgG
that just 1 mg/ml b12 IgG neutralized by 92% but permitted neutralized-virus (solid line). The percentage neutralization is indicated
in each panel.attachment of over 80% of virus to cells. Increasing the
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FIG. 5. Determination of the ability of b12 IgG or Fab to inhibit attachment of virus to C8166 cells. Dilutions of antibody were incubated with HIV-
1 (2 1 104 SFU). C8166 cells (106) were added and virus allowed to attach for 2 hr at 357. Cells were then washed with PBS and cell pellets were
lysed with 1% Empigen detergent. Virus attached to cells was detected by p24 ELISA. Neutralization was determined by culturing a sample of cells
removed from mixtures before the washing procedure and counting syncytia after 3 days incubation at 357. Attachment (bars) is expressed as the
percentage of virus bound in the presence and absence of antibody and is compared with neutralization (w). Normal human IgG did not neutralize
and did not affect attachment of virus to cells (data not shown).
does infectious virus. These experiments were controlled that this antibody inhibited the fusion-uncoating process
even though it did not inhibit attachment (see above). Inby the demonstration that, under the same conditions,
this experiment IgG b12 neutralized by 98.6%. In contrast,MAb F105 IgG neutralized by inhibiting attachment of
virus neutralized by b12 Fab to almost the extent (94.1%;virus to cells. Inhibition of virus attachment by F105 also
Fig. 6D) showed an increase in fluorescence that paral-verified that we were detecting virions with our anti-p24,
leled that of the nonneutralized control.rather than nonvirion p24 protein. In fact this was not a
problem as there was very little nonvirion p24 in the virus Neutralizing b12 IgG, but not b12 Fab, inhibits HIV-1-
preparation (Fig. 1), and srp24 did not bind to C8166 cells mediated cell–cell fusion
when added under conditions of virus infection (data not In order to confirm and extend data on virion–cell fu-
shown). Possible reasons why one human IgG1 CD4 sion, the ability of b12 IgG and Fab to inhibit HIV-infected
binding site MAb (F105) inhibits attachment of neutral- cell–cell fusion was quantitated. Infected and nonin-
ized virus to cells and another (b12) does not are dis- fected C8166 cells were incubated together in the pres-
cussed later. ence of various amounts of neutralizing b12 IgG or Fab.
IgG b12 reduced infectivity and fusion in parallel, with
Measurement of fluorescence dequenching shows 0.3 mg/ml IgG giving over 95% neutralization and 70%
that neutralizing b12 IgG, but not b12 Fab, inhibits the inhibition of fusion (Fig. 7). Increasing the antibody con-
fusion of HIV-1 virions to C8166 cells centration 20-fold to 6.3 mg/ml increased neutralization to
over 99% and reduced fusion activity by 90%. In contrastNonneutralized R18-labeled virus was incubated at 357
enough Fab (20 mg/ml) to effect 92% neutralization re-with C8166 cells and samples were taken at 0, 1, 2, and
duced the fusion activity by only 30%, while increasing3 hr. Figure 6A shows fluorescence dequenching took
the Fab concentration by threefold gave 99% neutraliza-place up to 3 hr, indicating that fusion was occurring over
tion but no further reduction in fusion (Fig. 7). A F(ab*)2this period. Three hours incubation gave the maximum
derived from b12 IgG by digestion with pepsin behavedfluorescence. Such a relatively slow fusion process was
exactly like the IgG in inhibiting fusion (data not shown).consistent with our other observations of virus entry (see
Clearly b12 IgG inhibited HIV-1-mediated fusion, whilebelow) and those of others, but at odds with another R18
b12 Fab did not. These and the foregoing data also indi-study in which fusion between HIV-1 (strain NIT) and
cate that b12 IgG inhibits both HIV-1 virion–cell and HIV-CEM cells reached a maximum in 10 min (Sinangil et al.,
1-mediated cell–cell fusion to a similar extent.1988). As a control, R18-labeled virus was incubated with
Immunofluorescence analysis shows that neutralizingthe CD40 A2.01 T cells, to which virus would be unable
b12 IgG but not Fab inhibits internalisation of HIV-1to attach specifically, and no increase of fluorescence
by HeLa-T4(CD4) cellswas observed (Fig. 6B). Incubation of virus neutralized
by b12 IgG with C8166 cells showed very little increase HeLa-T4(CD4) cells were used for immunofluores-
cence studies since T lymphoblastoid cells, like thein fluorescence and thus fusion (Fig. 6C), demonstrating
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FIG. 6. Fluorescence dequenching that occurs when R18-labeled HIV-1 infects C8166 cells was inhibited by neutralization with B12 IgG, but not
with b12 Fab. Virus or virus–antibody mixtures were held at 357 for 1 hr, and then incubated with CD4/ C8166 cells (A, C, D) or with CD40 A2.01
cells for 1, 2, or 3 hr at 357 (B). Cells were then fixed and fluorescence was assessed by FACS analysis. Virus was neutralized by b12 IgG to 98.6%
(C) or by b12 Fab to 94.1% (D). (A) Nonneutralized virus inoculated onto C8166 cells; (B) nonneutralized virus inoculated onto A2.01 cells; (C) b12
IgG-neutralized virus inoculated onto C8166 cells; (D) b12 Fab-neutralized virus inoculated onto C8166 cells. Virus–cell mixtures were incubated
for 0 hr, solid peak; 1 hr, dashed line; 2 hr, dotted line; and 3 hr, solid line.
C8166 cell line, have insufficient cytoplasm to allow reso- b12 IgG attached to cells in amounts indistinguishable
from nonneutralized virus. However, this pattern of sur-lution of the intracellular distribution of viral proteins.
Neutralization of HIV-1 in HeLa-T4(CD4) cells was re- face fluorescence did not change after incubation at 357
for 3 hr (Fig. 8f), and by 6 hr had decreased in intensityquantitated, and the entry of virus followed using anti-
p24 and anti-gp41 antibodies (Fig. 8). Although the cyto- (Fig. 8g). Initially the same amounts of cell surface gp41
were present as in the nonneutralized control cells (dataplasm of the HeLa-T4(CD4) cells was never as well
spread as in nontransfected HeLa cells, the major cell not shown), but by 3 hr this was barely detectable (Fig.
8h), whereas there was no loss of staining in the nonneu-structures could be clearly seen. Anti-p24 antibody stain-
ing of nonneutralized virus attached to cells at room tem- tralized control (Fig. 8d). These data are consistent with
the conclusion that b12 IgG did not inhibit attachment ofperature (0 hr) showed diffuse fluorescence over the cell
surface (Fig. 8a). In all, 97% infected cells showed this neutralized virus to cells, but inhibited the fusion–entry
process. This agrees completely with the direct measure-characteristic fluorescence, compared with only 2% of
noninfected cells (Fig. 8m). Following incubation at 357 ment of b12 IgG-inhibition of fusion shown above in Figs.
6 and 7. The coordinate loss of gp41 and p24 is probablyfor 3 and 6 hr, the distribution of virion p24 changed
completely with antigen migrating into the cytoplasm and due to the slow elution of attached virus from the cell
surface.perinuclear region (Figs. 8b and 8c). In contrast, gp41
remained on the cell surface although with some aggre- In contrast virus that was neutralized by b12 Fab by
99.3% showed the same pattern of immunostaining ofgation (Fig. 8d). Noninfected cells reacted with anti-gp41
antibody did not stain (Fig. 8n). These data are consistent virion p24 and gp41 as nonneutralized virus (compare
Figs. 8i– l with 8a–d). Note that after incubation at 357with the accepted view that HIV-1 infects cells by the
fusion of the viral and plasma membranes, with the sub- the patterns of staining with anti-p24 (Figs. 8j and 8k)
and with anti-gp41 antibodies (Fig. 8l) no longer corre-sequent entry of the virion core (virion RNA, p24, and
other proteins) into the cytoplasm. sponded. Thus these data are consistent with the inter-
pretation that b12 Fab did not inhibit attachment of virusFigure 8e confirms that virus neutralized by 99.6% by
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FIG. 7. B12 IgG inhibited HIV-1-mediated cell–cell fusion, while b12 Fab did not. Aliquots of infected cells were incubated with increasing
concentrations of antibody for 1 hr prior to the addition of noninfected C8166 cells at a ratio of 1:10. Cells were fixed after 3 hr incubation at 357,
aliquots removed, and the percentage fusion (hatched bars) was determined by counting syncytia. Approximately 103 cells were counted from each
sample. The baseline level of fusion in a sample incubated without antibody was measured immediately following mixing of the cells (i.e., time 0)
and results corrected for this value. Fusion observed in samples incubated in the presence of antibody are expressed as a percentage of fusion
measured in a control incubated without antibody. Neutralizing activity (w) was determined using the same antibody dilutions. Nonimmune human
IgG did not neutralize or inhibit cell fusion (solid bar).
to the cell and did not inhibit the fusion of viral and of removal of HIV-1 from cells by trypsin, and this paral-
leled the neutralization of infectivity. These quantitativecellular membranes. The fact that the staining of virion
p24 and gp41 was not coordinated after incubation at data are consistent with the view that resistance to tryp-
sin reflects fusion entry of virus and that b12 IgG inhibits357 is consistent with a fusion mechanism of virus entry
and does not support the view that virus entered the cell the fusion–entry process of HIV-1 but b12 Fab does not.
by endocytosis. These data are all in accord with the
failure of b12 Fab to inhibit HIV-1-mediated virion–cell DISCUSSION
and cell–cell fusion (Figs. 6 and 7).
Here we have investigated the mechanisms of neutral-Quantitation based on counts of approximately 1000
ization of HIV-1 IIIB by b12, a human IgG1 and b12 Fabcells was carried out on cells immunostained for p24
that recognizes an epitope in the region of the CD4-and supported the above conclusions. At 3 hr postinfec-
binding site of gp120. Both b12 IgG1 and Fab neutralizedtion, 96% cells inoculated with nonneutralized virus
efficiently, with the IgG having a 10-fold higher specificshowed the cytoplasmic pattern of fluorescence de-
activity than b12 Fab both on a molar basis and ac-scribed above, while 12% still had the diffuse fluores-
cording to their neutralization rate constants. However,cence of virus attached to but not fused with the cell
even though b12 is one of the most active HIV-1-neu-surface. The data for cells inoculated with b12 Fab-neu-
tralizing antibodies yet described, its neutralization ratetralized virus were in close agreement with 90% cyto-
constant is only around 10% of the constants of the bestplasmic and 9% surface fluorescence. However, cells
poliovirus and influenza virus IgG MAbs (Icenogle et al.,inoculated with b12 IgG-neutralized virus were in com-
1983; McLain and Dimmock, 1994; D. J. Schofield andplete contrast with 1% having cytoplasmic fluorescence
N. J. Dimmock, unpublished data). Taken at face value,and 97% with the original diffuse surface pattern.
this means that the maximum protective efficiency of
HIV-1 neutralizing antibodies in vivo is unlikely to beNonneutralized HIV-1 and virus neutralized with b12
attained until antibodies with a neutralizing activity in-Fab become resistant to removal from C8166 cells by
creased by about 10-fold can be obtained. However, neu-trypsin, while virus neutralized by b12 IgG does not
tralization rate constants vary with both viral isolate and
target cell (Dimmock, 1993) and our data obtained withNearly all nonneutralized virus that attached to cells
at 47 can be removed by treatment with trypsin, as dem- laboratory-adapted virus and a T cell line may prove to
be an over-estimate compared to those expected withonstrated by ELISA or by immunofluorescence (data not
shown). However, on incubation at 357, virus became primary virus isolates and primary cells.
Neutralization with both IgG1 and Fab followedprogressively resistant to such treatment. Representative
data in Fig. 9 show that HIV-1 treated with b12 Fab also pseudo-first order (single-hit) kinetics. In terms of protec-
tive immunity this would seem to be an advantage overbecame resistant to removal by trypsin from C8166 cells.
In contrast, b12 IgG completely inhibited the acquisition other MAbs which have multi-hit kinetics and neutralize
AID VY 8547 / 6a36$$$181 06-10-97 11:08:18 vira AP: Virology
322
AID VY 8547 / 6a36$$8547 06-10-97 11:08:18 vira AP: Virology
323NEUTRALIZATION OF HIV-1
FIG. 9. B12 IgG inhibited the acquisition of resistance to removal of HIV-1 from C8166 cells by incubation with trypsin, while b12 Fab did not.
Virus was preincubated with dilutions of antibody and then allowed to attach to C8166 cells for 2 hr at room temperature. There is no appreciable
virus–cell fusion under these conditions. Nonattached virus was removed by washing and cells incubated for a further 3 hr at 357. One-half of the
cell suspension was then treated with trypsin to remove attached virus and the other half mock-digested to give the total cell-associated virus.
Both were lysed with Empigen and virion p24 measured by ELISA. Virus resistant to trypsin treatment (hatched bars) is expressed as a percentage
of the nonneutralized virus control and is compared with the amount of neutralization (w). Normal human IgG did not neutralize or affect resistance
to trypsin (solid bar). Neutralization was determined by culturing aliquots of cells after nonattached virus had been removed by washing.
with a delay of up to 15 min (McLain and Dimmock, 1994). srgp120 to srCD4 and was affected by mutations in
amino acids which are known to contribute to bindingThe interpretation of the order of reaction in terms of the
number of molecules of antibody per virion required for site activity (Barbas III et al., 1992; Roben et al., 1994).
An explanation may be that inhibition by b12 Fab of theneutralization is uncertain (Dimmock, 1993). If it means
that one molecule of antibody per virion is required, there binding of one monomer of srgp120 to srCD4 requires a
1:1 stoichiometry, whereas neutralization can be effectedis a problem in explaining how a virus like HIV-1 can be
neutralized since HIV-1 has 225 or 300 molecules of by a number of antibody molecules per virion which is
far from saturating (for examples, see Dimmock, 1993).gp120 [assuming there are 75 envelope spike proteins
(Gelderblom et al., 1987) and that each is a trimer (as Failure of b12 IgG and Fab to inhibit attachment of neu-
tralized virus to cells is in accord with their single-hitsuggested by the trimerisation of the MA (p17) protein;
Hill et al., 1996) or a tetramer (Pinter et al., 1989; Scha- kinetics of neutralization (Fig. 3), since neutralization by
inhibition of attachment requires inhibition of at leastwaller et al., 1989)]. Alternatively the kinetic neutralization
curves in Fig. 3 can be explained by fractional neutraliza- several ligand–receptor interactions that would inevita-
bly have multi-hit kinetics (for example, by MAb F105 ortion, whereby each of x bound antibody molecules re-
duces infectivity by 1/x-fold (Icenogle et al., 1983). sCD4: L. McLain and N. J. Dimmock, unpublished data).
The above and other data on HIV-1 (Lasky et al., 1987Our data on the mechanism of neutralization show that
HIV-1 neutralized by b12 IgG1 attached to C8166 cells and personal communication; Schnittman et al., 1988)
and rabies virus (Bracci et al., 1988; Cusi et al., 1991)via the CD4 receptor, and that attachment of neutralized
virus to cells was not inhibited (Figs. 4, 5, and 8). This was showing that antibodies which effectively block the
monomer envelope protein–cell receptor interaction docontrolled with MAb F105, another human IgG1, which
clearly neutralized by inhibiting attachment of virus to not neutralize, suggesting that this assay has little rele-
vance to the interaction of virus particles and cells incells in our system and that of others (Figs. 4A and 4B;
Posner et al., 1991), and supported by the ability of b12 general and to neutralization in particular. The binding
of b12 Fab, unlike other members of a panel of similarlyIgG to neutralize virus after it had attached to cells (un-
published data). Failure of b12 to inhibit attachment might derived recombinant anti-HIV-1 MAbs, was significantly
diminished by the deletion of the V1, V2, and, to a lesserseem surprising as it had been mapped to the CD4 bind-
ing site of gp120, through inhibiting binding of monomeric extent, V3 loops of gp120 (Roben et al., 1994) and sug-
FIG. 8. Immunofluorescence analysis of the fate of the p24 and gp41 proteins of nonneutralized and neutralized HIV-1 virions (V) inoculated onto
HeLa-T4(CD4) cells. Nonneutralized virus or virus incubated with b12 IgG (V / b12) or b12 Fab (V / Fab b12) were allowed to attach to cells at
room temperature for 2 hr and then incubated at 357 for the times shown. Cells were inoculated with nonneutralized virus, incubated for 0, 3, or 6
hr at 357, and immunostained with anti-p24 IgG (a–c respectively) or an anti-gp41 MAb after 6 hr at 357 (d). Other cells were inoculated with b12
IgG neutralized virus and incubated for 0, 3, or 6 hr at 357 and immunostained with anti-p24 (e–g, respectively), or with anti-gp41 (3 hr only shown,
h). Still other cells were inoculated with b12 Fab-neutralized virus and incubated for 0, 3, or 6 hr at 357 and immunostained with anti-p24 (i–k,
respectively),or with anti-gp41 (3 hr only shown, l); (m) and (n) are noninfected (n.i.) cell controls stained with anti-p24 and anti-gp41, respectively.
B12 IgG and b12 Fab gave 99.6 and 99.3% neutralization, respectively. The bar represents 40 mm.
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gested that b12 Fab recognized different epitopes from paratope orientation (Thomas et al., 1985; Mosser et al.,
other anti-CD4 binding site antibodies and that b12 may 1989). (An IgG molecule is unlikely to cross-link adjacent
recognize a region proximal to or only partly overlapping envelope spikes of HIV-1 since their center-to-center dis-
the CD4 binding site. tance is about 28–35 nm, given that the diameter of the
Since b12 IgG and Fab neutralized without inhibiting virion is approximately 109 nm (Nermut et al., 1993) and
attachment of virus to target cells, their effect on virion that there are about 75 envelope projections per virion
entry into the cell, the next stage of infection, was deter- (Gelderblom et al., 1987). The longest dimension of the
mined by using several different techniques, including top surface of the gp120 oligomer is 15 nm (Gelderblom
the ability of virions to fuse with the cell plasma mem- et al., 1987), so that the distance between projections
brane by fluorescence dequenching (Fig. 6), virus-medi- will be approximately 13–20 nm, whereas the span of a
ated cell–cell fusion (Fig. 7), and direct visualization of human IgG1 molecule is approximately 9–15 nm (Valen-
virion proteins by immunofluorescence (Fig. 8). B12 IgG tine and Green, 1967; Werner et al., 1972; Gopalnakrish-
did not inhibit attachment of virus to cells, as discussed nan and Karush, 1974)). Alternatively, b12 IgG may block
above, but clearly inhibited the fluorescence dequench- fusion sterically, although b12 F(ab*)2 , derived by pepsin
ing that indicates that virion–cell fusion has taken place digestion, neutralized and inhibited fusion as well as the
(Fig. 6). In corroboration of this, b12 IgG quantitatively IgG (data not shown). Thus any steric effect would be
inhibited virus-mediated cell–cell fusion in direct propor- finely balanced as the F(ab*)2 and Fab have Mr of about
tion to the extent of neutralization (Fig. 7). Immunofluores- 100,000 and 50,000, respectively. It is interesting that b12
cence studies of the interaction of HIV-1 virions with IgG is one of three fusion-inhibiting MAbs that are able
target cells, which have not been reported before, con- to neutralize HIV-1 after it has attached to cells (Arm-
firmed all these observations (Fig. 8). The failure of virion strong and Dimmock, 1996; data not shown). Other MAbs
p24 of b12 IgG-neutralized virus to acquire resistance to are unable to do so at physiological temperature.
removal with trypsin (Fig. 9) also is quantitatively consis- We have concluded that b12 IgG neutralizes by inhib-
tent with inhibition of fusion entry by b12 IgG. Thus four iting virus–cell fusion while b12 Fab inhibits a postentry
lines of evidence independently suggest that b12 IgG stage of infection. This raises the possibility that the IgG
neutralizes HIV-1 by inhibiting the fusion entry process possesses both neutralizing activities and in effect kills
into the target cell. However, the virus–cell interactions HIV-1 twice over. A similar inference was made about
observed with b12 Fab-neutralized virus were profoundly an influenza A virus neutralizing antibody that inhibited
different. In experiments conducted simultaneously, b12
the fusion entry process, when it was found that artifi-
Fab had little effect on virus–cell fusion, on HIV-mediated
cially fusing the virus with the cell using polyethylene
cell–cell fusion, and in the immunofluorescence study
glycol (PEG) did not reverse neutralization (Armstrong
the patterns of p24 and gp41 staining were indistinguish-
and Dimmock, 1992). Nonneutralized influenza virus be-able from those of nonneutralized virus (Fig. 8). In addi-
came fully infectious when treated with PEG.tion, Fig. 9 shows that the acquisition of resistance to
The conclusion that neutralization by b12 Fab acts atremoval by trypsin of virus attached to cells was unaf-
a postfusion stage is intriguing. Details of the nature orfected by Fab neutralization. Together these data demon-
total number of uncoating events undergone by the virionstrate that b12 Fab neutralized HIV-1 without hindering
are not known, but the subvirion particles undergo sev-either the attachment or fusion entry processes. Thus
eral complex stages of uncoating before the first macro-we conclude that b12 Fab neutralizes by inhibiting an
molecular synthetic event by reverse transcriptase canevent that occurs after entry of the virus core into the
commence, and the mature preintegration complex iscell has taken place. What this event might be and why
completed. These include uncoating of the MA (p17)it differs from the mechanism of neutralization of b12 IgG
core, the CA (p24) nucleocapsid, and the ribonucleopro-is discussed below.
tein, where uncoating involves physical removal from theThe observation that an IgG and its Fab neutralize by
virion core and phosphorylation reactions (Bukrinskayadifferent mechanisms has not been previously reported.
et al., 1996; Gallay et al., 1996), and possibly conforma-The difference in their mode of action may result from
tional changes. B12 Fab probably acts indirectly sincethe ability of the IgG to attach bivalently to an envelope
fusion of virus and cell plasma membrane leaves theprotein and cross-link its constituent gp120 molecules.
Fab on the outside of the cell and the virion core on theThis is likely to be intraoligomer crosslinking as envelope
inside of the cell. It might prevent one of the postfusionproteins are calculated to be too far apart to permit in-
entry events from taking place or activate one of themterspike crosslinking unless the epitopes were at the
at an inappropriate time or location. There are parallelsperiphery (see below). Such crosslinking might confer a
with some influenza A mabs (reviewed in Dimmock, 1993,rigidity which abrogated fusion with the cell membrane.
1995). The mechanism(s) by which such neutralizing anti-However, we have no evidence that this antibody actually
bodies can affect postinternalization events remain(s) toattaches bivalently, and indeed some antibodies cannot
bind bivalently to a single virion due to the epitope – be determined.
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